ArticleEuropean journal of immunology2021

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.

Bo Mi Ku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.